Orchid Pharma Limited (BOM:524372)
India · Delayed Price · Currency is INR | Market Cap | 49.66B +54.0% |
| Revenue (ttm) | 8.11B -12.0% |
| Net Income | 205.47M -79.4% |
| EPS | 4.05 -79.4% |
| Shares Out | n/a |
| PE Ratio | 241.67 |
| Forward PE | 28.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,580 |
| Open | 1,012.10 |
| Previous Close | 1,009.85 |
| Day's Range | 969.00 - 1,016.50 |
| 52-Week Range | 471.30 - 1,096.40 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 976.00 (-0.6%) |
| Earnings Date | May 25, 2026 |
About Orchid Pharma
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly... [Read more]
Financial Performance
In fiscal year 2026, Orchid Pharma's revenue was 8.11 billion, a decrease of -12.00% compared to the previous year's 9.22 billion. Earnings were 205.47 million, a decrease of -79.38%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for 524372 stock is "Strong Buy." The 12-month stock price target is ₹976.00, which is a decrease of -0.60% from the latest price.
News
Orchid Pharma in focus as company advances US out-licensing talks for antibiotic enmetazobactam
Shares of Orchid Pharma Ltd may remain in focus after the company disclosed that it is in advanced discussions to out-license its novel antibiotic enmetazobactam in the United States, a…
Pharma sector stocks today June 15: Orchid Pharma up 4.90%, Strides Pharma gains 3.86%, Ajanta Pharma falls 2.32%
Pharma stocks traded mixed on June 15, 2026, during the early morning session, with gains and losses spread across the sector even as the broader market surged. The Nifty 50…
Orchid Pharma receives NCLT approval for merger with Dhanuka Laboratories
Orchid Pharma Limited has received approval from the National Company Law Tribunal (NCLT) for its merger with Dhanuka Laboratories Limited. The scheme of amalgamation, which aims to streamline operati...
Pharma sector stocks today, June 8: Orchid Pharma up 3.81%, Torrent Pharma gains 1.75%, Sudeep Pharma falls 2.05%
Pharma stocks traded mixed on June 8, 2026, during the morning session, with a majority of stocks posting gains while a few remained under selling pressure. The broader market was…
Orchid Pharma receives NCLT approval for amalgamation with Dhanuka Laboratories
Orchid Pharma Limited has received approval from the National Company Law Tribunal (NCLT) in Chennai for its amalgamation with Dhanuka Laboratories Limited. The tribunal's sanctioning of the scheme of...
Orchid Pharma Transcript: Q4 25/26
FY 2026 saw stable Q4 revenue and EBITDA, but full-year results declined due to industry-wide pricing pressures. Strategic initiatives, including the Dhanuka merger and new product launches, position the company for recovery and growth, with 10–15% sales growth targeted for FY 2027.
Orchid Pharma Quarterly report: Q4 2026
Orchid Pharma has published its Q4 2026 quarterly earnings report on May 26, 2026.
Orchid Pharma Slides: Q4 2026
Orchid Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 26, 2026.
Pharma Stocks Today, May 13: Wockhardt rises 1.97%, Orchid Pharma falls 1.79%, Biocon gains 1.38%
Indian pharmaceutical stocks showed a mixed trend on May 13 2026 during the early morning trading session. The BSE Healthcare index remained nearly flat, rising marginally by 0.04% to 46,087.93.…
Pharma sector stocks fall today, May 12: Orchid Pharma falls 3.74%, J.B. Chemicals down 2.67%, Biocon rises 0.79%
Indian pharmaceutical stocks opened lower on May 12 2026. The BSE Healthcare index declined 0.74% to 46,474.08 in the early morning trade. The broader market also remained weak with the…
Pharma sector stocks fall today, May 12: Orchid Pharma falls 3.74%, J.B. Chemicals down 2.67%, Torrent Pharma drops 2%
Indian pharmaceutical stocks opened lower on May 12 2026. The BSE Healthcare index declined 0.74% to 46,474.08 in the early morning trade. The broader market also remained weak with the…
Pharma sector stocks today, April 29: Orchid Pharma surges 3.35%, Torrent Pharma up 1.78%, Glenmark Pharma rises 1.72%
The Indian pharmaceutical sector opened on a broadly positive note on April 29, 2026. Of the 24 pharma stocks tracked, the majority are trading in the green in early trade…
Pharma stocks surge today, April 23: Dr. Reddy's Lab gains 6.43%, Strides Pharma rises 5.01%, Orchid Pharma surges 5.77%
Shares of pharmaceutical sector companies traded broadly higher on April 23, 2026, with Dr. Reddy's Laboratories, Strides Pharma Science, Orchid Pharma, and Glenmark Pharma among the standout gainers,...
Pharma sector stocks surge today, April 15: Indoco Remedies up 5%, Orchid Pharma gains 4.04%, Dr. Reddy's falls 1.64%
Indian pharmaceutical sector stocks traded higher in early morning trade on Tuesday, April 15, 2026, with most counters advancing while Dr. Reddy's Laboratories remained an outlier on the downside. Am...
Orchid Pharma Transcript: Q3 25/26
Q3 FY26 saw a 5% YoY sales decline and margin compression due to global antibiotic market stress and lower regulated market sales. Cost optimization and R&D investments continue, while new launches and the 7-ACA project are expected to drive future growth.
Orchid Pharma Quarterly report: Q3 2026
Orchid Pharma has published its Q3 2026 quarterly earnings report on February 12, 2026.
Orchid Pharma Slides: Q3 2026
Orchid Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 12, 2026.
Orchid Pharma shares slip over 3% as Q3 EBITDA falls 94.2% YoY to Rs 1.5 crore
Orchid Pharma shares slipped more than 3% in early trade on February 12 (IST) after the company reported a sharp...
Orchid Pharma Transcript: Q2 25/26
Q2 FY26 saw a 13% YoY sales decline but sequential improvement, with gross margin compression due to weak pricing and inventory liquidation. Strategic acquisition of emmetazobactam rights positions for future growth, while the antibiotics market remains under pressure.
Orchid Pharma Quarterly report: Q2 2026
Orchid Pharma has published its Q2 2026 quarterly earnings report on November 11, 2025.
Orchid Pharma Slides: Q2 2026
Orchid Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 11, 2025.
Orchid Pharma Transcript: Q1 25/26
Q1 FY26 saw a 29% sales decline due to a global antibiotics slowdown, but gross margins were preserved at 42%. The company acquired global rights to Enmetazobactam, expects no debt for the deal, and is focused on disciplined execution and margin protection amid ongoing market contraction.
Orchid Pharma Quarterly report: Q1 2026
Orchid Pharma has published its Q1 2026 quarterly earnings report on August 12, 2025.
Orchid Pharma Slides: Q1 2026
Orchid Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 12, 2025.
Top stocks to buy today: Stock recommendations for July 16, 2025 - check list
Stock market recommendations: Anand Rathi Shares suggests buying Tilak Nagar Industries, Orchid Pharma, and ITC. Tilak Nagar Industries shows range breakout with volume support. Orchid Pharma indicate...